PHARMACIE DE L'HOPITAL : revenue, balance sheet and financial ratios

In 2024, PHARMACIE DE L'HOPITAL achieves revenue of 4.1 M€. Over the period 2017-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +16.9%. Slight decline of -9% vs 2023. After deducting consumption (2.9 M€), gross margin stands at 1.2 M€, i.e. a rate of 30%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 556 k€, representing 13.4% of revenue. Warning negative scissor effect: despite revenue change (-9%), EBITDA varies by -28%, reducing margin by 3.6 pts. This reflects costs rising faster than revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 369 k€, i.e. 8.9% of revenue. This profit can be retained or distributed to shareholders.

The debt ratio (= Financial debt / Equity x 100) stands at 47%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 49%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.9 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 11.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

The liquidity ratio (= Current assets / Current liabilities) stands at 274.60. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 2.5x. Financial charges are adequately covered by operations.

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 15 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 26 days. Favorable situation: supplier credit is longer than customer credit by 11 days. Inventory turnover is 59 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 67 days of revenue, i.e. 768 k€ to permanently finance. Over 2017-2024, WCR increased by +407%, requiring additional financing.

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE DE L'HOPITAL is estimated at 4 392 719 € (range 3 065 664€ - 6 534 901€). With an EBITDA of 556 262€, the sector multiple of 9.2x is applied. The price/revenue ratio is 0.64x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.